FibroBiologics (FBLG) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 22, 2026, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 21, 2026.

Voting matters and shareholder proposals

• Election of Pete O'Heeron as Class III Director to serve until 2029.

• Ratification of WithumSmith + Brown, PC as independent auditor for the year ending December 31, 2026.

• Approval of issuance of up to 2,431,819 shares of Common Stock upon exercise of outstanding warrants related to March 2026 Securities Purchase Agreements and an amended engagement letter.

• Approval of the 2026 Equity and Incentive Compensation Plan.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals presented at the meeting.